Target intelligence / Profile preview

Activator of 90 kDa heat shock protein ATPase homolog 1 (AHSA1)

Target
AHSA1
Molecular classification
Co-chaperone, Chaperone regulator, Protein folding modulator, Bet v1-like protein superfamily, Other
01

Overview

Activator of 90 kDa heat shock protein ATPase homolog 1 (AHSA1) is a co-chaperone protein that binds and stimulates the ATPase activity of Hsp90, a vital molecular chaperone involved in protein folding, maturation, and trafficking[1][4][5]. AHSA1 modulates conformational dynamics at the dimer interface of Hsp90, impacting the “dwell time” of client proteins and regulating critical cellular functions, including kinase activation, signal transduction, and protein quality control[1][4][5][7]. Dysregulation or altered expression of AHSA1 is associated with cancer progression, neurodegenerative diseases, and other conditions hallmarked by aberrant protein folding[3][4]. While no drugs directly target AHSA1 yet, it is considered a promising therapeutic target due to its regulatory role in Hsp90-dependent processes[1][4].

Other names
AHA1C14orf3HSPC322p38hAha1activator of HSP90 ATPase activity 1activator of heat shock 90 kDa protein ATPase homolog 1
02

Mechanism of action

Small molecules or biologics that inhibit AHSA1 would reduce Hsp90 ATPase activation, impairing chaperone function and destabilizing oncogenic or misfolded proteins\nAntisense or RNAi knockdown reduces protein folding and trafficking of mutant client proteins (e.g., CFTR, tau)

03

Biological functions

Positive regulation of ATP-dependent activityStimulates Hsp90 ATPase activityProtein folding and maturationModulates client protein traffickingProtein quality controlRegulates kinase and non-kinase clientsInfluences alternative splicingInvolvement in cell signaling
04

Disease associations

Cancer (implicated in progression and regulation of oncogenic kinases)Neurodegenerative disease (involved in tau protein aggregation and Alzheimer’s disease)Protein misfolding disordersOther
05

Safety considerations

Risk of disrupting essential protein folding processes and cellular homeostasisPossible off-target effects leading to toxicity due to widespread effects on proteostasisPotential impact on immune cell infiltration and signaling
06

Interacting drugs

No approved direct drugs, but Hsp90 inhibitors may indirectly interact (e.g., geldanamycin derivatives, tanespimycin, radicicol)

1 more in the full profile.

07

Biomarkers

AHSA1 expression in tumors (prognostic biomarker in pan-cancer studies)AHSA1 level as a biomarker for protein misfolding disease status

Beyond the preview

Go deeper on Activator of 90 kDa heat shock protein ATPase homolog 1 (AHSA1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Activator of 90 kDa heat shock protein ATPase homolog 1 (AHSA1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call